BiotechTube

ICL670 + deferoxamine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Beta-Thalassemia

Conditions

Beta-Thalassemia

Trial Timeline

May 1, 2003 → —

NCT ID
NCT00061750

About ICL670 + deferoxamine

ICL670 + deferoxamine is a phase 3 stage product being developed by Novartis for Beta-Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00061750. Target conditions include Beta-Thalassemia.

What happened to similar drugs?

2 of 6 similar drugs in Beta-Thalassemia were approved

Approved (2) Terminated (0) Active (4)
✅DeferasiroxNovartisApproved
✅ICL670NovartisApproved
🔄deferasiroxNovartisPhase 3
🔄CTX001Vertex PharmaceuticalsPhase 3
🔄CTX001Vertex PharmaceuticalsPhase 3
🔄CTX001Vertex PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00061750Phase 3Completed

Competing Products

18 competing products in Beta-Thalassemia

See all competitors
ProductCompanyStageHype Score
ACE-536MerckPhase 2
42
DeferasiroxNovartisApproved
43
Zoledronic acid + PlaceboNovartisPhase 2/3
34
deferasiroxNovartisPhase 3
40
DeferasiroxNovartisPhase 2
35
DeferasiroxNovartisPhase 2
35
ICL670NovartisApproved
43
BitopertinRochePhase 2
35
Luspatercept + PlaceboBristol Myers SquibbPhase 2
39
CTX001Vertex PharmaceuticalsPhase 3
44
CTX001Vertex PharmaceuticalsPhase 3
47
CTX001Vertex PharmaceuticalsPhase 2/3
38
CTX001Vertex PharmaceuticalsPhase 3
47
Mozobil + Mozobil + MozobilSanofiPre-clinical
26
Deferitrin (GT56-252) + desferoxamine (DFO)SanofiPhase 1/2
32
REGN7999 + PlaceboRegeneron PharmaceuticalsPhase 2
42
VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + PlaceboLabCorpPhase 2
24
VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + PlaceboLabCorpPhase 2
32